Advanced Code injection

obio 10/21/14 obio 10/21/14

Vasomune Therapeutics awarded $1.5 million to advance lead asset for renal disease

obio 10/16/14 obio 10/16/14

Xagenic Appoints Timothy I. Still as President & Chief Executive Officer

obio 10/15/14 obio 10/15/14

Xagenic Announces $6 Million Genome Canada Funded Project in Partnership with University of Toronto

obio 10/11/14 obio 10/11/14

Theralase Partners with SAFC in Manufacture of Anti-Cancer Drugs

obio 10/5/14 obio 10/5/14

Proteocyte Diagnostics Highest Ranked Life Sciences Company in NACO’s Most Promising Canadian Startup of the Year Competition

obio 10/5/14 obio 10/5/14

Rna Diagnostics Awarded Patent for Test that Guides Cancer Chemotherapy

obio 9/29/14 obio 9/29/14

AvidBiologics Closes New Financing Round

obio 9/17/14 obio 9/17/14

AbCelex Technologies Inc. Secures an Additional $1 Million in Series A Financing

obio 9/13/14 obio 9/13/14

Entrepreneur redevelops one of life’s scariest tests

obio 8/1/14 obio 8/1/14

OBIO Celebrates Five Years Advancing Ontario's Human Health Technology and Bioscience Ecosystem

obio 8/1/14 obio 8/1/14

BLG LifeSigns Article: Ontario Bioscience Innovation Organization - OBIO

obio 5/16/14 obio 5/16/14

Armour Therapeutics discovers synergies between prostate cancer treatment and conventional chemotherapy to treat aggressive tumours

obio 5/16/14 obio 5/16/14

AbCelex Technologies Secures Two Million in Series A Financing

obio 5/16/14 obio 5/16/14

Kevin Egan Joins Sernova as Chair Business Advisory Board

obio 5/16/14 obio 5/16/14

Interface Biologics Appoints Dion Madsen to Board of Directors

obio 5/8/14 obio 5/8/14

Sernova Announces Appointment of Nick Borrelly to Corporate Development Role

obio 4/28/14 obio 4/28/14

Sernova’s Cell Pouch™ Diabetes Clinical Trial Demonstrates Interim Safety and Biocompatibility

obio 4/18/14 obio 4/18/14

Spectral Updates Status Of EUPHRATES Trial

obio 4/18/14 obio 4/18/14

Profound Medical Announces Closing of Enrollment Into TULSA Clinical Trial for Treatment of Localized Prostate Cancer

obio 4/9/14 obio 4/9/14

Critical Outcome Technologies Applies for Orphan Drug Designation for COTI-2 Treatment of Ovarian Cancer